2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG, Investigators V. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal 2018, 206: 11-23. PMID: 30290289, DOI: 10.1016/j.ahj.2018.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood GlucoseBridged Bicyclo Compounds, HeterocyclicCardiovascular DiseasesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDouble-Blind MethodEuropeFemaleFollow-Up StudiesGlycated HemoglobinHumansIncidenceMaleMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsSurvival RateTreatment OutcomeUnited StatesConceptsAtherosclerotic cardiovascular diseaseCardiovascular outcome trialsCV deathHeart failureComposite outcomeOutcome trialsMajor adverse CV eventsStage 3 kidney diseaseType 2 diabetes mellitusEfficacy of ertugliflozinVERTIS-CV trialAdverse CV eventsNonfatal myocardial infarctionDouble-blind placeboPeripheral arterial diseaseCoronary artery diseasePeripheral arterial systemCV eventsERTugliflozin effIcacyNonfatal strokeRenal safetyDiabetes durationBaseline characteristicsRenal deathSerum creatinine
2013
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal Of Medicine 2013, 369: 799-808. PMID: 23808982, DOI: 10.1056/nejmoa1302507.Peer-Reviewed Original ResearchConceptsAcute venous thromboembolismConventional therapy groupPrimary efficacy outcomeVenous thromboembolismMajor bleedingConventional therapyApixaban groupRelevant nonmajorEfficacy outcomesRecurrent symptomatic venous thromboembolismOral factor Xa inhibitorsFixed-dose regimenPrincipal safety outcomeSymptomatic venous thromboembolismDouble-blind studyFactor Xa inhibitorsOral apixabanAdverse eventsComposite outcomeRelative riskThromboembolismXa inhibitorsApixabanSafety outcomesBleeding
2002
Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-2898. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.Peer-Reviewed Original ResearchConceptsEstrogen-deficient womenIL-6/ILSkeletal sensitivityIL-6IL-6sREstrogen deficiencyCytokine systemIL-6 soluble receptorUrine N-telopeptideAction of PTHPrevious animal studiesNTx excretionPTH infusionPostmenopausal womenSerum calciumN-telopeptideCytokine productionTNF-alphaExaggerated increaseIL-1betaHormonal statusBaseline valuesSoluble receptorAnimal studiesColony-stimulating factor-1
1998
The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis
Masiukiewicz US, Insogna KL. The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Aging Clinical And Experimental Research 1998, 10: 232-239. PMID: 9801733, DOI: 10.1007/bf03339657.Peer-Reviewed Original ResearchConceptsParathyroid hormonePostmenopausal womenPrimary hyperparathyroidismBone lossSecondary hyperparathyroidismAnabolic therapyPostmenopausal osteoporosisBone massVitamin D. Parathyroid hormoneDaily subcutaneous administrationRecent therapeutic trialsVitamin D metabolismTrabecular bone massTherapeutic trialsD metabolismBone turnoverBone resorptionSurgical correctionSubcutaneous administrationHyperparathyroidismVivo effectsSingle agentTissue responsivenessSustained increaseCortical sites